NasdaqHealth CarePharmaceutical PreparationsCLEVELAND, OH

Abeona Therapeutics Inc. ABEO

Ask your AI

Estimated market cap $138.30M57.15M shares, shares as of Nov 5, 2026CIK 318306

Insider trades, 12 mo

0 buys · 37 sells

$3.50M sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q2 2026

127

77.9% of shares · 43 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Abeona Therapeutics Inc.'s latest quarterly report, compared with the one before.

Filed Nov 9, 2026 · Quarter ended Sep 30, 2026

AI No AI summary for this 10-Q: the draft did not pass our accuracy checks.

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Abeona Therapeutics Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

37 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Sep 29, 2026. Insiders have two business days to file.

Recent insider trades

Vishwas Seshadri Chief Executive Officer, Director	Sep 29 Form 4 ↗	Sale	−$101.2K 19,608 sh @ $5.16	-51.8%
Joseph Walter Vazzano Chief Financial Officer	Sep 29 Form 4 ↗	Sale	−$47.4K 9,191 sh @ $5.16	-51.8%
Brendan M. O'Malley SVP, Chief Legal Officer	Sep 29 Form 4 ↗	Sale	−$34.7K 6,727 sh @ $5.16	-51.8%
Madhav Vasanthavada Chief Commercial Officer	Sep 29 Form 4 ↗	Sale	−$25.3K 4,902 sh @ $5.16	-51.8%
Mark Alvino Director	Sep 1 Form 4 ↗	Sale	−$87.9K 15,000 sh @ $5.86	-58.6%

All ABEO insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

44.53M shares

127 funds report ABEO. Values checked against market prices.

Funds own 78% of shares (Q2 2026)

127 funds hold the stock.

Q3 2026: 47% · 5,560 of ~8,900 funds reported so far

Q2 202568%
Q3 202566%
Q4 202572%
Q1 202669%
Q2 202678%
Q3 2026 (so far)47%

Reports for the quarter ending Sep 30, 2026 are still coming in (73 positions so far, against 147 the quarter before), so we compare the two complete quarters before it.

Q2 2026. 32 new, 43 added to, 32 trimmed, 13 exited since Q1 2026.

Top 13F holders
#
1	Nantahala Capital Management, LLC 13F ↗	10.27M	$63.5M	+104.9%
2	BlackRock, Inc. 13F ↗	3.35M	$20.7M	+4.9%
3	Cable Car Capital, LP 13F ↗	3.01M	$18.6M	unchanged
4	AIGH Capital Management LLC 13F ↗	2.99M	$18.5M	-3.6%
5	Vanguard Capital Management LLC 13F ↗	2.21M	$13.7M	+2.2%
6	OneDigital Investment Advisors LLC 13F ↗	1.65M	$10.2M	New
7	AWM Investment Company, Inc. 13F ↗	1.49M	$9.2M	+85.0%
8	Geode Capital Management, LLC 13F ↗	1.26M	$7.8M	+4.2%
9	Kennedy Capital Management LLC 13F ↗	1.24M	$7.7M	-1.9%
10	Goldman Sachs Group Inc 13F ↗	1.22M	$7.6M	+8.3%

Download CSV Every fund that holds ABEO, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Abeona Therapeutics Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Abeona Therapeutics Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report, adjusted for splits

Funds holding the stock by quarter

Q2 2022	1	—	1,391	$169.0K
Q3 2022	22	+21	1.04M	$3.2M
Q4 2022	41	+19	8.17M	$28.5M
Q1 2023	33	-8	7.53M	$21.2M
Q2 2023	37	+4	9.39M	$37.9M
Q3 2023	40	+3	12.48M	$52.5M
Q4 2023	48	+8	16.41M	$82.2M
Q1 2024	56	+8	14.53M	$105.4M
Q2 2024	48	-8	33.65M	$142.7M
Q3 2024	55	+7	28.82M	$182.1M
Q4 2024	64	+9	30.62M	$170.4M
Q1 2025	71	+7	29.67M	$141.2M
Q2 2025	95	+24	34.91M	$198.3M
Q3 2025	100	+5	35.87M	$189.4M
Q4 2025	104	+4	38.93M	$205.2M
Q1 2026	108	+4	39.53M	$177.1M
Q2 2026	127	+19	44.53M	$275.1M
Q3 2026	69	-58	26.64M	$139.9M

Each point is a quarter-end, from Q2 2022 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (00289Y206). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2022) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits (1-for-25 on Jul 5, 2022): reports from before a split are multiplied by its ratio, so every quarter is on the share count of Q3 2026.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes11 in 12 mo 8-K events3 in 90 days Patents2 patents granted Short interestFINRA · updated Oct 15 Planned insider salesForm 144 · 32 in 12 mo Executive pay3 fiscal years Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials4 active Merger clearancesLatest Jun 24 Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: ABEONA THERAPEUTICS INC.
Address: 6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, OH 44103
Phone: 646-813-4701
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: DE
Listed as: ABEO (Nasdaq)
Former names: PLASMATECH BIOPHARMACEUTICALS INC (until 2015); ACCESS PHARMACEUTICALS INC (until 2014); CHEMEX PHARMACEUTICALS INC (until 1996)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$2.42+$0.13 (+5.68%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $2.29 · High $4.65Nov 13, 2026

Aug 13, 2026Low $2.29 · High $6.35Nov 13, 2026

Nov 13, 2025Low $2.29 · High $7.46Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.